Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.68% to $432.00 Tuesday, on what proved to be an all-around mixed trading ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex Pharmaceuticals Incorporated’s VRTX first-quarter results were weak as it missed estimates for both earnings and sales ...

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff plans, then bounced back big once he said he would pause expanded tariffs ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.

Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...

Vertex Pharmaceuticals' (NASDAQ ... Vertex noted that illegal copycat versions of its products in the country are negatively impacting sales. However, the company believes the problem is isolated ...